Skip to main content

Macular Edema clinical trials at UCLA

5 in progress, 2 open to eligible people

Showing trials for
  • OCS-01 in Subjects With Uveitis Related and Post Surgical Macular Edema

    open to eligible people ages 18 years and up

    The goal of the LEOPARD clinical trial is to investigate a new kind of steroid eye drops, OCS-01. Macular edema is a condition in which there is collection of fluid (edema) in the back of the eye (Macula) and it can lead to severe loss of vision. Among other causes, macular edema can happen because of a disease of the eye called Uveitis, and also after eye surgery. Treatment of macular edema remains a challenge as the condition may persist for several months and may lead to irreversible changes in the eye and poor vision. In the LEOPARD study the investigators wish to see how safe is the study drug (OCS-01) and how well it works, in resolving the fluid collection in the eye in patients with Uveitis or in patients who have had eye surgery. Participants will undergo detailed eye exam, and record their eye and medical history to see what their disease status is and if they can be included in the study based on the study criteria. If included, they will take the study drug OCS-01 in different doses for 24 weeks. During the study period, they will have regular eye exams to ensure their safety and to assess the usefulness of the study drug.

    Los Angeles, California and other locations

  • Vamikibart in Participants With Uveitic Macular Edema

    open to eligible people ages 18 years and up

    This study will assess the efficacy and safety of vamikibart in participants with uveitic macular edema.

    Los Angeles, California and other locations

  • Vamikibart (RO7200220) in Combination With Ranibizumab in Diabetic Macular Edema

    Sorry, in progress, not accepting new patients

    Study BP43464 is a phase II, multicenter, randomized, double-masked active comparator-controlled study designed to assess the efficacy, safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of vamikibart in combination with, anti-vascular endothelial growth factor (VEGF) inhibitor, ranibizumab compared with ranibizumab alone in participants with diabetic macular edema. Only one eye will be chosen as the study eye. The duration of the study will be 76 weeks.

    Torrance, California and other locations

  • Vamikibart (RO7200220) in Diabetic Macular Edema

    Sorry, in progress, not accepting new patients

    Study BP43445 is a phase II, multicenter, randomized, double-masked, active comparator-controlled study to investigate the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of vamikibart administered intravitreally in participants with diabetic macular edema. Only one eye will be chosen as the study eye. The duration of the study will be up to 76 weeks.

    Torrance, California and other locations

  • Predicting Diabetic Retinopathy From Risk Factor Data and Digital Retinal Images

    Sorry, in progress, not accepting new patients

    The objective of this study is to compare the results of a deep learning approach to diabetic retinopathy assessment with results from (1) an in-person examination with an ophthalmologist, and (2) the assessments of optometrists involved in a teleretinal screening program.

    Los Angeles, California and other locations

Last updated: